Compounds > carocainide
Page last updated: 2024-12-06

carocainide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Carocainide is a local anesthetic that has been studied for its potential therapeutic applications, particularly in the treatment of pain. Its synthesis involves a complex chemical process that involves the use of various reagents and reaction steps. Carocainide is known to exert its effects by blocking the transmission of nerve impulses, leading to a loss of sensation in the treated area. This mechanism of action is attributed to its ability to bind to and block voltage-gated sodium channels in nerve membranes. Carocainide has shown promising results in preclinical studies, demonstrating efficacy in pain management. It is studied due to its potential to offer an alternative to existing local anesthetics, particularly for certain types of pain that are not well-managed with current treatments. Further research is underway to evaluate its safety, efficacy, and potential benefits in clinical settings.'

carocainide: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71970
CHEMBL ID289192
SCHEMBL ID1815397
MeSH IDM0116699

Synonyms (19)

Synonym
urea, 1-(4,7-dimethoxy-6-(2-(1-pyrrolidinyl)ethoxy)-5-benzofuranyl)-3-methyl-
n-(4,7-dimethoxy-6-(2-pyrrolidinoethoxy)-5-benzofuranyl)-n'-methylurea
1-(4,7-dimethoxy-6-(2-(1-pyrrolidinyl)ethoxy)-5-benzofuranyl)-3-methylurea
carocainide
carocainida [inn-spanish]
brn 5154193
carocainide [inn]
carocainidum [inn-latin]
einecs 266-233-7
CHEMBL289192
1-[4,7-dimethoxy-6-(2-pyrrolidin-1-ylethoxy)-1-benzofuran-5-yl]-3-methylurea
66203-00-7
carocainida
unii-t643e80j9k
t643e80j9k ,
carocainidum
SCHEMBL1815397
DTXSID00216381
Q27289715

Research Excerpts

Overview

Carocainide is a new benzofuran derivative showing antiarrhythmic properties in animal models.

ExcerptReferenceRelevance
"Carocainide is a new benzofuran derivative showing antiarrhythmic properties in animal models. "( Electrophysiological effects of carocainide (770207) on canine ventricular muscle and Purkinje fibers.
Pourrias, B; Santamaria, R, 1983)		1.99
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID58775Duration for the antiarrhythmic activity was measured1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antiarrhythmic activity of new benzofuran derivatives.
AID60854Activity against harris coronary ligation induced ventricular arrhythmia was measured as percent of final sinus complexes after dose 5 mg/kg iv1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antiarrhythmic activity of new benzofuran derivatives.
AID60844Activity against harris coronary ligation induced ventricular arrhythmia was measured as percent of final sinus complexes after dose 12.5 mg/kg, po1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antiarrhythmic activity of new benzofuran derivatives.
AID134765Toxicity estimated in mouse as LD50 by intravenous administration1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antiarrhythmic activity of new benzofuran derivatives.
AID58776Duration for the sinus rhythm recovery was measured1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antiarrhythmic activity of new benzofuran derivatives.
AID59516Activity against harris coronary ligation induced ventricular arrhythmia was measured as percent of initial sinus complexes after dose 20 mg/kg, po1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antiarrhythmic activity of new benzofuran derivatives.
AID59376Activity against harris coronary ligation induced ventricaulr arrhythmia was measured as percent of initial sinus complexes after dose 12.5 mg/kg po1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antiarrhythmic activity of new benzofuran derivatives.
AID60851Activity against harris coronary ligation induced ventricular arrhythmia was measured as percent of final sinus complexes after dose 2 mg/kg iv1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antiarrhythmic activity of new benzofuran derivatives.
AID60848Activity against harris coronary ligation induced ventricular arrhythmia was measured as percent of final sinus complexes after dose 20 mg/kg, po1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antiarrhythmic activity of new benzofuran derivatives.
AID60845Activity against harris coronary ligation induced ventricular arrhythmia was measured as percent of final sinus complexes after dose 12.5 mg/kg, po1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antiarrhythmic activity of new benzofuran derivatives.
AID61884Activity against ouabain-induced ventricular arrhythmia was measured as percent of sinus rhythm recovery at dose of 2 mg/kg iv1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antiarrhythmic activity of new benzofuran derivatives.
AID60853Activity against harris coronary ligation induced ventricular arrhythmia was measured as percent of final sinus complexes after dose 2 mg/kg, po1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antiarrhythmic activity of new benzofuran derivatives.
AID59526Activity against harris coronary ligation induced ventricular arrhythmia was measured as percent of initial sinus complexes after dose 5 mg/kg iv1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antiarrhythmic activity of new benzofuran derivatives.
AID59522Activity against harris coronary ligation induced ventricular arrhythmia was measured as percent of initial sinus complexes after dose 2 mg/kg, iv1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antiarrhythmic activity of new benzofuran derivatives.
AID59521Activity against harris coronary ligation induced ventricular arrhythmia was measured as percent of initial sinus complexes after dose 2 mg/kg po1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antiarrhythmic activity of new benzofuran derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.15 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
disopyramide
Disopyramide: A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.. disopyramide : A monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug.		1.9610monocarboxylic acid amide;
pyridines;
tertiary amino compound		anti-arrhythmia drug
ouabain
Ouabain: A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like DIGITALIS. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-EXCHANGING ATPASE.. cardiac glycoside : Steroid lactones containing sugar residues that act on the contractile force of the cardiac muscles.. ouabain : A steroid hormone that is a multi-hydroxylated alpha-L-rhamnosyl cardenoloide. It binds to and inhibits the plasma membrane Na(+)/K(+)-ATPase (sodium pump). It has been isolated naturally from Strophanthus gratus.		1.961011alpha-hydroxy steroid;
14beta-hydroxy steroid;
5beta-hydroxy steroid;
alpha-L-rhamnoside;
cardenolide glycoside;
steroid hormone		anti-arrhythmia drug;
cardiotonic drug;
EC 2.3.3.1 [citrate (Si)-synthase] inhibitor;
EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
ion transport inhibitor;
plant metabolite
quinidine
Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.		1.9610cinchona alkaloidalpha-adrenergic antagonist;
anti-arrhythmia drug;
antimalarial;
drug allergen;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
muscarinic antagonist;
P450 inhibitor;
potassium channel blocker;
sodium channel blocker
tetrodotoxin
Tetrodotoxin: An aminoperhydroquinazoline poison found mainly in the liver and ovaries of fishes in the order TETRAODONTIFORMES, which are eaten. The toxin causes paresthesia and paralysis through interference with neuromuscular conduction.. tetrodotoxin : A quinazoline alkaloid that is a marine toxin isolated from fish such as puffer fish. It has been shown to exhibit potential neutotoxicity due to its ability to block voltage-gated sodium channels.		1.9610azatetracycloalkane;
oxatetracycloalkane;
quinazoline alkaloid		animal metabolite;
bacterial metabolite;
marine metabolite;
neurotoxin;
voltage-gated sodium channel blocker
ConditionIndicatedRelationship StrengthStudiesTrials
Ventricular Fibrillation
A potentially lethal cardiac arrhythmia that is characterized by uncoordinated extremely rapid firing of electrical impulses (400-600/min) in HEART VENTRICLES. Such asynchronous ventricular quivering or fibrillation prevents any effective cardiac output and results in unconsciousness (SYNCOPE). It is one of the major electrocardiographic patterns seen with CARDIAC ARREST.		01.9610
A-V Dissociation
[description not available]		01.9610
Tachyarrhythmia
[description not available]		01.9710
Tachycardia
Abnormally rapid heartbeat, usually with a HEART RATE above 100 beats per minute for adults. Tachycardia accompanied by disturbance in the cardiac depolarization (cardiac arrhythmia) is called tachyarrhythmia.		01.9710
Drop Attack
[description not available]		01.9610
Paroxysmal Reciprocal Tachycardia
[description not available]		01.9610
Syncope
A transient loss of consciousness and postural tone caused by diminished blood flow to the brain (i.e., BRAIN ISCHEMIA). Presyncope refers to the sensation of lightheadedness and loss of strength that precedes a syncopal event or accompanies an incomplete syncope. (From Adams et al., Principles of Neurology, 6th ed, pp367-9)		01.9610
Tachycardia, Paroxysmal
Abnormally rapid heartbeats with sudden onset and cessation.		01.9610